DDX17 and hepatocellular carcinoma: Previous data showed that DDX17 could regulate alternative splicing and produce oncogenic molecules that promote hepatocellular carcinoma metastasis, indicating that DDX17 expression was strongly associated with patient outcomes (Zhou et al., 2022).